NCT02734160 - A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

August 2, 2018

Study Completion Date

April 17, 2019

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Galunisertib

Administered orally

DRUG

Durvalumab

Administered IV

Trial Locations (11)

Memorial Sloan Kettering Cancer Center, New York

Hospital Universitario 12 de Octubre, Madrid

Hospital Madrid Norte Sanchinarro, Madrid

Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona

Sarah Cannon Research Institute SCRI, Nashville

Tennessee Oncology PLLC, Nashville

Honor Health Research Institute, Scottsdale

Gustave Roussy, Villejuif

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Hospital Universitari Vall d'Hebron, Barcelona